Want to take quizzes and track your credits?
Eight randomized clinical trials of tocilizumab for treating patients with COVID-19 have reported heterogeneous results.1- 6 Although 4 of them achieved their primary end point, improved 28-day survival was demonstrated only in the 2 largest studies and those with the highest mortality, RECOVERY1 and REMAP-CAP.2 Moreover, only RECOVERY enrolled only patients with elevated C-reactive protein (CRP) levels. The RECOVERY and REMAP-CAP trials involved a high rate of patients using dexamethasone (>80% of the patients in both treatment arms). Differences in trial outcomes may be associated with differences in power, populations, design, management, or length of follow-up.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: March 31, 2021.
Published Online: May 24, 2021. doi:10.1001/jamainternmed.2021.2209
Corresponding Author: Xavier Mariette, MD, PhD, Department of Rheumatology, Hôpital Bicêtre, 78 Av du Général Leclerc, 94275, Le Kremlin Bicêtre, France (firstname.lastname@example.org).
Correction: This article was corrected on June 28, 2021, to fix an incorrectly named scale in the Results.
Author Contributions: Drs Porcher and Resche-Rigon had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mariette, Hermine, Tharaux, Resche-Rigon, Ravaud.
Acquisition, analysis, or interpretation of data: Mariette, Tharaux, Resche-Rigon, Steg, Porcher, Ravaud.
Drafting of the manuscript: Mariette, Hermine, Tharaux.
Critical revision of the manuscript for important intellectual content: Mariette, Resche-Rigon, Steg, Porcher, Ravaud.
Statistical analysis: Resche-Rigon, Porcher, Ravaud.
Obtained funding: Mariette, Hermine, Resche-Rigon.
Administrative, technical, or material support: Resche-Rigon, Steg.
Supervision: Mariette, Hermine, Tharaux, Ravaud.
Conflict of Interest Disclosures: Dr Steg reported personal fees from Amarin, Amgen, AstraZeneca, BMS, Idorsia, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier, and Regeneron as well as grants from Bayer, Sanofi, Servier, and Amarin outside the submitted work. Dr Ravaud reported being a minority shareholder of INATO outside the submitted work. No other disclosures were reported.
Funding: This trial was publicly funded (Ministry of Health, Programme Hospitalier de Recherche Clinique [PHRC COVID-19-20-0143, PHRC COVID-19-20-0029] and Foundation for Medical Research).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the members of the CORIMUNO-19 collaborative group.
Data Sharing Statement: See Supplement 3.
You currently have no searches saved.